Literature DB >> 21461853

Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study.

L L Zhang1, J X Zhao, X Y Liu.   

Abstract

SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a rare disease. Presently, there is no treatment guideline for this illness. Several studies suggested entercept, a novel biological agent against tumor necrosis factor-alpha, is effective in treating SAPHO syndrome. We report a case in which the clinical conditions of a middle-aged female patient diagnosed with SAPHO syndrome, with noted spinal disorder, improved significantly after receiving entercept treatment. The patient remained stable after 3-month follow-up.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21461853     DOI： 10.1007/s00296-011-1916-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  6 in total

1.  Successful treatment of SAPHO syndrome with infliximab: report of two cases.

Authors:  I Olivieri; A Padula; G Ciancio; C Salvarani; L Niccoli; F Cantini
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

2.  Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.

Authors:  Annette D Wagner; Jan Andresen; Michael C Jendro; Jan L Hülsemann; Henning Zeidler
Journal:  Arthritis Rheum       Date:  2002-07

Review 3.  Off-label dermatologic uses of anti-TNF-a therapies.

Authors:  Andrew F Alexis; Bruce E Strober
Journal:  J Cutan Med Surg       Date:  2005-12       Impact factor: 2.092

4.  In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations.

Authors:  A Massara; P L Cavazzini; F Trotta
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

5.  Successful treatment of SAPHO syndrome with an oral bisphosphonate.

Authors:  Jiro Ichikawa; Eiichi Sato; Hirotaka Haro; Takashi Ando; Singo Maekawa; Yoshiki Hamada
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

6.  Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.

Authors:  N Pennanen; S Lapinjoki; A Urtti; J Mönkkönen
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200
  6 in total
  6 in total

Review 1.  SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment.

Authors:  Davide Firinu; Vanessa Garcia-Larsen; Paolo Emilio Manconi; Stefano R Del Giacco
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

2.  Etanercept in the treatment of refractory SAPHO syndrome.

Authors:  Lei Zhang; Zhaomeng Gao
Journal:  Am J Clin Exp Immunol       Date:  2016-11-30

3.  Etanercept in the treatment of SAPHO syndrome: Which place?

Authors:  Fatima Ezzahra Abourazzak; Hicham Hachimi; Nadira Kadi; Khadija Berrada; Siham Tizniti; Taoufik Harzy
Journal:  Eur J Rheumatol       Date:  2014-09-01

4.  Multimodal imaging findings of SAPHO syndrome with no skin lesions: A report of three cases and review of the literature.

Authors:  Na Duan; Xiao Chen; Yongkang Liu; Jianhua Wang; Zhongqiu Wang
Journal:  Exp Ther Med       Date:  2016-09-08       Impact factor: 2.447

Review 5.  New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.

Authors:  Wei Cheng; Fen Li; Jing Tian; Xi Xie; Jin-Wei Chen; Xiao-Fei Peng; Qi Tang; Yan Ge
Journal:  J Inflamm Res       Date:  2022-04-13

6.  Long-term Clinical Outcomes in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.

Authors:  Francis H X Yap; Deborah Olsson-White; Janet Roddy; Nicola J Cook; D Robert Langlands; Prue J Manners; Graeme J Carroll
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.